Fibrotic disorders represent one of the largest groups of diseases for which there is no therapy. It has long been known that the matricellular protein CCN2 (connective tissue growth factor, CTGF) is (a) rapidly induced by fibrogenic cytokines such as TGFβ and (b) highly expressed in a wide range of fibrotic conditions (Igarashi et al. 1993; Blom et al. 2002) . Based on these observations, and that fibrogenic activities can be attributable to CCN2, the notion emerged that CCN2 could represent a novel target for anti-fibrotic drug intervention (Goldschmeding et al. 2000; Moussad and Brigstock, 2000; Leask et al. 2002) . As discussed in an earlier Bits and Bytes, precise evidence using has finally emerged that clearly indicates that CCN2 is indeed required for experimental fibrosis (Leask, 2011) .
Several different strategies that target the profibrotic action of CCN2 have emerged; for example, using siRNA, a hammerhead ribozyme, antisense RNA or specific antibodies (Sisco et al. 2008; Gao and Brigstock, 2009; Brigstock, 2009; Ponticos et al. 2009; Wang et al. 2011) . These strategies are aimed at generally blocking CCN2 expression or action. However, CCN2 has functions other than promoting fibrosis (Leask and Abraham, 2006) ; thus a better approach may be to uncover methods of directly targeting CCN2's pro-fibrotic actions.
To develop such a selective anti-fibrotic approach, it might be wise to block specific interactions between CCN2 and its receptors/ligands. The mechanism of action for CCN2 is complex, owing to the fact that CCN2, as an adhesive protein, can bind many different ligands including integrins and components of the extracellular matrix (Leask and Abraham, 2006; Chen and Lau, 2009; Perbal, 2004) . For example, CCN2 possesses a heparin-binding domain; indeed, CCN2 can interact with a variety of heparan sulfate-containing proteoglycans (HSPGs) (Leask and Abraham, 2006: Chen and Lau, 2010; Gao and Brigstock, 2005) . These latter proteins, although found on the cell surface, can also be soluble; thus it is possible that individual HSPGs could represent novel, anti-fibrotic therapeutic approaches through their ability to block CCN2 action.
In a recent report, Vial and colleagues (2011) test this latter hypothesis by exploring whether the HSPG decorin, which has previously been shown to suppress TGFβ activity (Kolb et al. 2001) , regulates CCN2 action on cells. To begin to investigate this issue, the authors used a C2C12 myoblast cell line deficient in decorin to show, that in the absence of decorin, CCN2 potently induces expression of fibronectin. Moreover, they showed that recombinant decorin blocked the ability of CCN2 to induce fibronectin expression in C2C12 cells. Decorin and CCN2 bound each other directly; the authors delineated the precise region of decorin (in leucine rich repeats peptide 12) that was responsible for this interaction. CCN2 was also able to induce decorin expression, providing a method of controlling the action of endogenous CCN2 protein.
These exciting data not only provide evidence of yet another HSPG that can interact with CCN2, but also provide a biologically-based method of selectively interfering with the pro-fibrotic action of CCN2 using a relatively small peptide. It would be interesting to ascertain whether the leucine rich repeats peptide 12 region of decorin could reverse experimental fibrosis in vivo.
